Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data

Background Contemporary use of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and angiotensin receptor‐neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF) has not been described. Methods and Results We analyzed the MarketScan databases for the period Jan...

Full description

Bibliographic Details

Published in:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Main Authors:	Alvaro Alonso, Alanna A. Morris, Ashley I. Naimi, Aniqa B. Alam, Linzi Li, Vinita Subramanya, Lin Yee Chen, Pamela L. Lutsey
Format:	Article
Language:	English
Published:	Wiley 2024-03-01
Subjects:	angiotensin receptor‐neprilysin inhibitors atrial fibrillation heart failure sodium‐glucose cotransporter‐2 inhibitors
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.123.032783